Government confirms commitment to uncapped PBS in Australia

2 April 2019

Medicines Australia welcomes the announcement of A$331 million ($236 million) for the listings of innovative medicines on the country’s Prescription Benefits Scheme (PBS) in today’s 2019/20 Federal Budget. This is reinforced by the Morrison government’s commitment to listing all positive recommendations made by the Pharmaceutical Benefits Advisory Committee.

Medicines Australia chief executive Elizabeth de Somer said: “The Morrison government has recognized that medicines matter and confirmed their commitment to the uncapped PBS and overall health expenditure. This will help ensure all Australians have access to new and innovative medicines they need when they need them.

The Treasurer announced overall health portfolio spending will increase by A$20 billion over forward estimates, from A$102 billion in 2018-19 to A$115 billion in 2022-2023. The forward estimates show a A$40 billion spend on the PBS consistent with previous years reporting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK